HEPA — Hepion Pharmaceuticals Share News
0.000.00%
Last trade - 00:00Brief: Hepion Pharma In-Licenses Diagnostic Tests from New Day Diagnostics- SEC Filing
Brief: Hepion Pharmaceuticals Announces Termination Of Merger Agreement With Pharma Two B
Brief: Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B
Brief: Pharma Two B Plans To Go Public Via Merger With Hepion Pharmaceuticals, Concurrent $11.5 Mln Private Placement
U.S. STOCKS ON THE MOVE-EV stocks, Salesforce, Verizon
Hepion tumbles after discontinuing trial for fatty liver disease treatment
Brief: Hepion Pharmaceuticals Initiates Wind-Down Activities In Phase 2B ‘Ascend-Nash’ Trial
Hepion Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Hepion Pharmaceuticals Inc expected to post a loss of $2.63 a share - Earnings Preview
Hepion Pharmaceuticals Inc expected to post a loss of $2.63 a share - Earnings Preview
Hepion Pharmaceuticals Inc expected to post a loss of $2.63 a share - Earnings Preview
Hepion Pharmaceuticals Inc expected to post a loss of $2.63 a share - Earnings Preview
Hepion Pharmaceuticals Inc expected to post a loss of $2.63 a share - Earnings Preview
Hepion Pharmaceuticals Inc expected to post a loss of $2.63 a share - Earnings Preview
Hepion Pharmaceuticals Inc expected to post a loss of $2.63 a share - Earnings Preview
Brief: Hepion Pharmaceuticals Appoints Michael Purcell To Board
Brief: Hepion Pharmaceuticals Says Gary Jacob Resigned From The Board Of Directors
Hepion Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary
Brief: Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat